It’s a seller’s world in biotech M&A, and Novartis CEO Vas Narasimhan has his check book out and pen ready
The Alcon spinoff is officially done today, debuting on the Swiss exchange with a market cap of $25 billion-plus, and Novartis CEO Vas Narasimhan is planning a long-running shopping spree in search of important new biotech products. And he’s been clearly focused on a late-stage strategy that has triggered a flashing red warning light at a world of potential rivals.
In several interviews, including this one with the Financial Times, the youngest CEO in Novartis history is newly liberated. He has a pipeline stuffed with drugs he’s certain are blockbusters-to-be, with 4 late-stage drugs set to launch this year — a remarkable achievement, especially as several of them really are tapped as blockbusters.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.